Skip to main content
Caplight Logo









Sunbird Bio

Sunbird Bio

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://sunbirdbio.com

Last Round

Early Funding

Oct 16, 2024

Total Funding Raised

$36M

Company Overview

Sunbird Bio is a biotechnology company that develops proprietary blood-based diagnostic tests to enable earlier, more accurate diagnosis and treatment of neurological disorders and early-stage cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Usage-Based SaaS

AI Layer

Non-AI

Keywords

biotechnologydiagnostic testsneurodegenerative diseaseliquid biopsyblood-based biomarkersAPEX platformAlzheimer's diagnosticsParkinson's diagnosticsprotein biomarkerprecision medicinepatient stratificationdrug development supportclinical diagnosticsbiomarker validationnon-invasive diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sunbird Bio Comparables

Compare Sunbird Bio with similar companies based on industry and business-model similarity.

Sunbird Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
C2N Diagnostics
82%
ADmit Therapeutics
79%
ALZpath, Inc.
79%

Sunbird Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingOct 16, 2024
M&AAug 9, 2023
VC RoundMay 12, 2023
Series AOct 11, 2018

Sunbird Bio Investors

Notable investors and investment history

Sunbird Bio investors
InvestorRounds
GreatPoint VenturesSeries A
S32Early Funding
ARCH Venture PartnersSeries A
ClavystBioEarly Funding
EDBIEarly Funding
Yonghua CapitalSeries A
Rivas CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 8, 2025

    Richard Batrla appointed as the new Chief Medical Officer.

  • Oct 16, 2024

    $14M raised with EDBI and Eli Lilly leading.

Sunbird Bio Filings

Explore SEC and related filing metadata, where available.

Sunbird Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Sunbird Bio's valuation, stock price, and market status.

Is Sunbird Bio a public or private company?

Sunbird Bio is a private company.

What is the current stock price of Sunbird Bio?

Sunbird Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Sunbird Bio worth (valuation)?

Valuation information for Sunbird Bio is not publicly available.

Can I buy Sunbird Bio stock?

Sunbird Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Sunbird Bio's last funding round?

Sunbird Bio's most recent funding round was Series A on October 16, 2024.

Who are the main investors in Sunbird Bio?

Key investors in Sunbird Bio include EDBI.

Will Sunbird Bio IPO soon?

No public IPO plans have been announced for Sunbird Bio.

How can I track Sunbird Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Sunbird Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range32
Year Founded2021
Last FundingOct 16, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?